Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18595757 | 0.79 | GRIA1 (0.38) | GRIA1GRIA4 | |
| SCHEMBL23872681 | 0.77 | GRIA1 (0.37) | GRIA1GRIA4 | |
| SCHEMBL26144750 | 0.77 | GRIA1 (0.37) | GRIA1GRIA4 | |
| SCHEMBL23872856 | 0.77 | GRIA1 (0.37) | GRIA1GRIA4 | |
| SCHEMBL23613117 | 0.76 | GRIA1 (0.35) | GRIA1ALDH1A1GRIA4 | |
| SCHEMBL25927575 | 0.74 | GRIA1 (0.34) | GRIA1L3MBTL1GRIA4 | |
| SCHEMBL1780393 | 0.73 | KDM4E (0.38) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL23872397 | 0.72 | GRIA1 (0.38) | GRIA1GRIA4 | |
| SCHEMBL8360658 | 0.72 | GRIA1 (0.39) | GRIA1KDM4EGRIA4 | |
| SCHEMBL19464753 | 0.71 | GRIA1 (0.41) | GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147507-A1 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | KIF18A, KIF18B, KIF2C | GRIA1 2715/4885KDM4E 1372/4885ALDH1A1 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.